{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:18:26Z","timestamp":1793085506246,"version":"4.5.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Foundation (NRF) funded by the Ministry of Science and ICT (MSIT), Republic of Korea","award":["2020R1A2C2102492"],"award-info":[{"award-number":["2020R1A2C2102492"]}]},{"name":"Korea Institute of Radiological and Medical Sciences (KIRAMS) funded by the Ministry of Science, ICT (MSIT), Republic of Korea","award":["50547-2022"],"award-info":[{"award-number":["50547-2022"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>To evaluate the prognostic value of pretreatment <jats:sup>18<\/jats:sup>F-FDG PET\/CT after consolidation therapy of <jats:sup>131<\/jats:sup>I-rituximab in patients with diffuse large B-cell lymphoma (DLBCL) who had acquired complete remission after receiving chemotherapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients who were diagnosed with DLBCL via histologic confirmation were retrospectively reviewed. All patients had achieved complete remission after 6 to 8 cycles of R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone) chemotherapy after which they underwent consolidation treatment with <jats:sup>131<\/jats:sup>I-rituximab. <jats:sup>18<\/jats:sup>F-FDG PET\/CT scans were performed before R-CHOP for initial staging. The largest diameter of tumor, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were obtained from pretreatment <jats:sup>18<\/jats:sup>F-FDG PET\/CT scans. Receiver-operating characteristic curves analysis was introduced for assessing the optimal criteria. Kaplan-Meier curve survival analysis was performed to evaluate both relapse free survival (RFS) and overall survival (OS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 15 patients (12 males and 3 females) with a mean age of 56 (range, 30\u201373) years were enrolled. The median follow-up period of these patients was 73 months (range, 11\u2013108 months). Four (27%) patients relapsed. Of them, three died during follow-up. Median values of the largest tumor size, highest SUVmax, MTV, and TLG were 5.3 cm (range, 2.0\u201316.4 cm), 20.2 (range, 11.1\u201367.4), 231.51 (range, 15\u201338.34), and 1277.95 (range, 238.37\u201310341.04), respectively. Patients with SUVmax less than or equal to 16.9 showed significantly worse RFS than patients with SUVmax greater than 16.9 (5-year RFS rate: 60% vs. 100%, <jats:italic>p<\/jats:italic> = 0.008). Patients with SUVmax less than or equal to 16.9 showed significantly worse OS than patients with SUVmax greater than 16.9 (5-year OS rate: 80% vs. 100% <jats:italic>p<\/jats:italic> = 0.042).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Higher SUVmax at pretreatment <jats:sup>18<\/jats:sup>F-FDG PET\/CT was associated with better relapse free survival and overall survival in DLBCL patients after consolidation therapy with <jats:sup>131<\/jats:sup>I-rituximab. However, because this study has a small number of patients, a phase 3 study with a larger number of patients is needed for clinical application in the future.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0273839","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T17:36:57Z","timestamp":1664213817000},"page":"e0273839","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of 18F-FDG PET\/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7735-761X","authenticated-orcid":true,"given":"Joon Ho","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-1659","authenticated-orcid":true,"given":"Ilhan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Hyun","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Woon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Moo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"issue":"6","key":"pone.0273839.ref001","first-page":"393","article-title":"Improving outcomes for patients with diffuse large B-cell lymphoma","volume":"60","author":"CR Flowers","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"pone.0273839.ref002","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/modpathol.2012.178","article-title":"Aggressive B-cell lymphomas: how many categories do we need?","volume":"26","author":"JW Said","year":"2013","journal-title":"Mod Pathol"},{"issue":"4","key":"pone.0273839.ref003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"B Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"19","key":"pone.0273839.ref004","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"TM Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18","key":"pone.0273839.ref005","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma","volume":"369","author":"PJ Stiff","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"pone.0273839.ref006","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1002\/cncr.24522","article-title":"A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia","volume":"115","author":"N Jain","year":"2009","journal-title":"Cancer"},{"issue":"32","key":"pone.0273839.ref007","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"F Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"issue":"25","key":"pone.0273839.ref008","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911","volume":"24","author":"OW Press","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0273839.ref009","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.12906","article-title":"R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433","volume":"166","author":"JW Friedberg","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"pone.0273839.ref010","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3109\/10428194.2015.1067701","article-title":"Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission","volume":"57","author":"M Shadman","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"pone.0273839.ref011","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00280-016-3140-5","article-title":"Radioimmunotherapy with (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma","volume":"78","author":"DY Shin","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"pone.0273839.ref012","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"ME Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"pone.0273839.ref013","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"BD Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0273839.ref014","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1743-7563.2011.01393.x","article-title":"Radioimmunotherapy with (131)I-rituximab for patients with relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma (NHL)","volume":"7","author":"HJ Kang","year":"2011","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"pone.0273839.ref015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2967\/jnumed.111.099531","article-title":"18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging","volume":"53","author":"EH Dibble","year":"2012","journal-title":"J Nucl Med"},{"issue":"9","key":"pone.0273839.ref016","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12149-012-0630-3","article-title":"Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods","volume":"26","author":"B Shah","year":"2012","journal-title":"Ann Nucl Med"},{"issue":"3","key":"pone.0273839.ref017","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.ijrobp.2010.12.055","article-title":"What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom","volume":"82","author":"M Werner-Wasik","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"pone.0273839.ref018","article-title":"Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial","author":"H Schoder","year":"2020","journal-title":"Blood"},{"issue":"2","key":"pone.0273839.ref019","doi-asserted-by":"crossref","first-page":"e0211649","DOI":"10.1371\/journal.pone.0211649","article-title":"Comparison of therapeutic evaluation criteria in FDG-PET\/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor\/liver ratio","volume":"14","author":"MN Toledano","year":"2019","journal-title":"PLoS One"},{"key":"pone.0273839.ref020","doi-asserted-by":"crossref","first-page":"9449","DOI":"10.2147\/CMAR.S218678","article-title":"Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET\/CT By Combining Deauville Scores And International Prognostic Index","volume":"11","author":"H Sun","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"20","key":"pone.0273839.ref021","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial","volume":"36","author":"U Duhrsen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0273839.ref022","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/ajh.23267","article-title":"The impact of baseline and interim PET\/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma","volume":"87","author":"S Park","year":"2012","journal-title":"Am J Hematol"},{"issue":"10","key":"pone.0273839.ref023","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","article-title":"Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis","volume":"48","author":"C Lin","year":"2007","journal-title":"J Nucl Med"},{"issue":"2","key":"pone.0273839.ref024","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000500512","article-title":"Prognostic Value of Pre-Autologous Stem Cell Transplantation PET\/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to DeltaSUVmax","volume":"143","author":"XY Zhang","year":"2020","journal-title":"Acta Haematol"},{"issue":"5","key":"pone.0273839.ref025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/ejh.12268","article-title":"F-18 FDG PET\/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma","volume":"92","author":"R Gallicchio","year":"2014","journal-title":"Eur J Haematol"},{"issue":"4","key":"pone.0273839.ref026","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12185-011-0822-y","article-title":"High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma","volume":"93","author":"D Chihara","year":"2011","journal-title":"Int J Hematol"},{"key":"pone.0273839.ref027","article-title":"High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP","author":"L Vercellino","year":"2020","journal-title":"Blood"},{"key":"pone.0273839.ref028","first-page":"1","article-title":"Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline (18)F-FDG PET-CT","author":"G Delaby","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"pone.0273839.ref029","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","article-title":"(18)F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome","volume":"61","author":"AS Cottereau","year":"2020","journal-title":"J Nucl Med"},{"issue":"7","key":"pone.0273839.ref030","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00259-019-04309-4","article-title":"Prognostic value of metabolic tumour volume on baseline (18)F-FDG PET\/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI","volume":"46","author":"QA Shagera","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0273839.ref031","first-page":"1","article-title":"PET-derived tumor metrics predict DLBCL response and progression-free survival","author":"P Islam","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"pone.0273839.ref032","doi-asserted-by":"crossref","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis","volume":"14","author":"B Guo","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"pone.0273839.ref033","first-page":"407","article-title":"Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing\/refractory non-hodgkin lymphoma following radioimmunotherapy","volume":"8","author":"R Taghvaei","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"7","key":"pone.0273839.ref034","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","author":"NG Mikhaeel","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"pone.0273839.ref035","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12032-014-0446-1","article-title":"Predictive value of F-18 FDG PET\/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants","volume":"32","author":"M Xie","year":"2015","journal-title":"Med Oncol"},{"issue":"10","key":"pone.0273839.ref036","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1007\/s00259-021-05233-2","article-title":"Baseline PET\/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review","volume":"48","author":"R Frood","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"pone.0273839.ref037","first-page":"1181","article-title":"Prognostic Value of (18)F-FDG PET\/CT Metabolic Parameters in Patients with Diffuse Large B-Cell Lymphoma","volume":"29","author":"JM Su","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"7","key":"pone.0273839.ref038","first-page":"528","article-title":"Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma","volume":"40","author":"CY Ding","year":"2018","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"1","key":"pone.0273839.ref039","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2967\/jnumed.108.055376","article-title":"18F-FDG PET\/CT for monitoring the response of lymphoma to radioimmunotherapy","volume":"50","author":"HA Jacene","year":"2009","journal-title":"J Nucl Med"},{"issue":"6","key":"pone.0273839.ref040","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2967\/jnumed.116.182675","article-title":"Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication","volume":"58","author":"S Park","year":"2017","journal-title":"J Nucl Med"},{"issue":"12","key":"pone.0273839.ref041","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00259-013-2506-8","article-title":"(18)F-FDG PET\/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy","volume":"40","author":"S Carkaci","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"pone.0273839.ref042","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"C Haioun","year":"2005","journal-title":"Blood"},{"issue":"1","key":"pone.0273839.ref043","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1148\/rg.301095088","article-title":"FDG PET\/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease","volume":"30","author":"FM Paes","year":"2010","journal-title":"Radiographics"},{"issue":"2","key":"pone.0273839.ref044","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: significance and impact on clinical outcome","volume":"26","author":"P Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"pone.0273839.ref045","first-page":"1426","article-title":"Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG","volume":"44","author":"AK Buck","year":"2003","journal-title":"J Nucl Med"},{"issue":"14 Pt 1","key":"pone.0273839.ref046","first-page":"4232","article-title":"High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy","volume":"12","author":"KH Lee","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"8","key":"pone.0273839.ref047","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.nucmedbio.2007.07.007","article-title":"Decreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro","volume":"34","author":"TA Smith","year":"2007","journal-title":"Nucl Med Biol"},{"issue":"4","key":"pone.0273839.ref048","first-page":"646","article-title":"In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line","volume":"42","author":"DE Lorke","year":"2001","journal-title":"J Nucl Med"},{"issue":"2","key":"pone.0273839.ref049","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000346436","article-title":"Prognostic significance of pretreatment (1)(8)F-FDG PET\/CT in patients with relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma treated by radioimmunotherapy using (1)(3)(1)I-rituximab","volume":"130","author":"I Lim","year":"2013","journal-title":"Acta Haematol"},{"issue":"3","key":"pone.0273839.ref050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3324\/haematol.10591","article-title":"Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin\u2019s lymphoma by 18F-fluorodeoxyglucose positron emission tomography","volume":"93","author":"C Bodet-Milin","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"pone.0273839.ref051","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00259-009-1275-x","article-title":"Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma","volume":"37","author":"T Cazaentre","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"pone.0273839.ref052","first-page":"436","article-title":"FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma","volume":"54","author":"E Lopci","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T17:38:17Z","timestamp":1664213897000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273839"}},"subtitle":[],"editor":[{"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":52,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273839","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}